elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35739806-EEA11E1A-236F-4334-B5A4-99C2ECF0B6BE
Q35739806-EEA11E1A-236F-4334-B5A4-99C2ECF0B6BE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35739806-EEA11E1A-236F-4334-B5A4-99C2ECF0B6BE
First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis.
P2860
Q35739806-EEA11E1A-236F-4334-B5A4-99C2ECF0B6BE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35739806-EEA11E1A-236F-4334-B5A4-99C2ECF0B6BE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
47138f2387eae990b253631a7a1f0f7b2d294087
P2860
Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types